HCA (HCA Healthcare) Research & Development: $0 Mil (TTM As of Mar. 2026)


HCA HCA Healthcare Inc HCA
93 GF Score
Price $387.76
GF Value $451.56
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is HCA Healthcare Research & Development?

HCA Healthcare HCA +0.22% 93 Research & Development is $0 Mil as of Mar. 2026. GuruFocus rates HCA with a GF Score™ of 93/100 and a GF Value™ of $451.56 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. HCA Healthcare's Research & Development for the three months ended in Mar. 2026 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0 Mil.

HCA Healthcare  (NYSE:HCA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

HCA Healthcare Research & Development Related Terms

HCA Healthcare Research & Development Historical Data

* Premium members only.

The historical data trend for HCA Healthcare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HCA Healthcare Research & Development Chart

HCA Healthcare Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HCA Healthcare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HCA
93GF Score
HCA Healthcare Inc HCA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HCA Healthcare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0 Mil mean?
HCA Healthcare (HCA) has a Research & Development of $0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on HCA Healthcare and its competitors.
Is HCA Healthcare's Research & Development too high?
HCA Healthcare's current Research & Development is $0 Mil. Overall, HCA Healthcare has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HCA Healthcare's Research & Development compare to THC and DVA?
HCA Healthcare's Research & Development of $0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on HCA Healthcare and its competitors. HCA Healthcare's current Research & Development is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCA Healthcare stock overvalued right now?
Based on GuruFocus' analysis, HCA Healthcare (HCA) is currently considered Modestly Undervalued. The stock's GF Value™ is $451.56, compared to a current price of $387.76 — trading 14.1% below its estimated fair value. The current Research & Development is $0 Mil. HCA Healthcare's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For HCA Healthcare (HCA), the current Research & Development is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HCA Healthcare (HCA) Overvalued in 2026?

Based on GuruFocus' analysis, HCA Healthcare stock appears to be undervalued. The current stock price of $387.76 is trading 14.1% below its estimated GF Value™ of $451.56. GuruFocus considers HCA Healthcare to be Modestly Undervalued.

Key valuation signals for HCA:

  • Research & Development: $0 Mil
  • GF Value™: $451.56 vs. price of $387.76 (14.1% below fair value)
  • GF Score™: 93/100 with 3 warning signs

No single metric tells the full story. See the HCA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HCA Healthcare Business Description

Address One Park Plaza, Nashville, TN, USA, 37203
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2025, the firm owned and operated 190 hospitals and over 2,500 outpatient facillities across 19 states and a small foothold in the United Kingdom.
93GF Score

Get the complete analysis for HCA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$387.76
Price
$451.56
GF Value